GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » Book Value per Share

Paradigm Biopharmaceuticals (ASX:PAR) Book Value per Share : A$0.10 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Paradigm Biopharmaceuticals Book Value per Share?

Paradigm Biopharmaceuticals's book value per share for the quarter that ended in Dec. 2023 was A$0.10.

During the past 12 months, Paradigm Biopharmaceuticals's average Book Value Per Share Growth Rate was -62.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -26.50% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Paradigm Biopharmaceuticals was 55.40% per year. The lowest was -26.50% per year. And the median was 46.30% per year.

Paradigm Biopharmaceuticals's current price is A$0.27. Its book value per share for the quarter that ended in Dec. 2023 was A$0.10. Hence, today's PB Ratio of Paradigm Biopharmaceuticals is 1.46.

During the past 8 years, the highest P/B Ratio of Paradigm Biopharmaceuticals was 15.43. The lowest was 0.00. And the median was 0.00.


Paradigm Biopharmaceuticals Book Value per Share Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Book Value per Share Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Book Value per Share
Get a 7-Day Free Trial 0.42 0.47 0.33 0.18 0.19

Paradigm Biopharmaceuticals Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.18 0.25 0.19 0.10

Competitive Comparison of Paradigm Biopharmaceuticals's Book Value per Share

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paradigm Biopharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's PB Ratio falls into.



Paradigm Biopharmaceuticals Book Value per Share Calculation

Paradigm Biopharmaceuticals's Book Value Per Share for the fiscal year that ended in Jun. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(53.68-0.00)/289.68
=0.19

Paradigm Biopharmaceuticals's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(33.80-0.00)/351.50
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Paradigm Biopharmaceuticals  (ASX:PAR) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Paradigm Biopharmaceuticals Book Value per Share Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Paradigm Biopharmaceuticals (ASX:PAR) Business Description

Traded in Other Exchanges
Address
500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).

Paradigm Biopharmaceuticals (ASX:PAR) Headlines